

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Alzheimer's disease (AD)	Low-density lipoprotein receptor (LDLR)	A study in mice suggests that agonizing LDLR could help treat AD. Mice overexpressing LDLR had lower levels of apolipoprotein E (ApoE), an LDLR ligand that contributes to AD pathology, than wild-type controls. In a mouse model of AD, LDLR-expressing animals had lower levels of $\beta$ -amyloid ( $A\beta$ ) plaques and neuroinflammation than wild-type controls. Next steps include determining what regulates LDLR expression in the brain.	Patent and licensing status undisclosed	Kim, J. <i>et al. Neuron</i> ; published online Dec. 10, 2009; doi:10.1016/j.neuron.2009.11.013 <b>Contact:</b> David M. Holtzman, Washington University School of Medicine in St. Louis, St. Louis, Mo. e-mail: <a href="mailto:holtzman@neuro.wustl.edu">holtzman@neuro.wustl.edu</a>
		<b>SciBX 3(2); doi:10.1038/scibx.2010.61</b> Published online Jan. 14, 2010		